Clinical Studies

Description: This project is dedicated to providing comprehensive postpartum care for birthing people and their newborns through integration and co-location of health services.

Eligibility: in development

⚲

Description: The objective of this study is to assess the effect of utilizing gender-transformative strategies - i.e., those targeting restrictive gender-based norms – to deliver family planning (FP) in the context of a public health infant vaccination program in rural India. Our central hypothesis is that integrating community-based FP care with the existing infant vaccination program will reach more rural postpartum women and improve uptake of postpartum contraception.

Eligibility (Inclusion): Postpartum people aged 18 and older, reside in rural Maharashtra, speak Marathi, delivered a baby within the past 8 weeks but did not undergo sterilization, hysterectomy or immediate postpartum IUD placement and do not have a new pregnancy.

Eligibility (Exclusion): Under 18 years old, delivered a baby more than 8 weeks prior or planning to move out of the study area within the next 6 months. 

⚲

Description: This study will assesses the impact of early initiation (less than one week postpartum) and delayed initiation (4 weeks postpartum) of two types of progestin-only contraceptive pills on maternal, breastmilk, and infant outcomes. This is a placebo-controlled randomized controlled trial enrolling dyads of birthing people and their newborn babies. We will explore if the type and timing of initiation of pills is acceptable to the user with minimal side effects, impacts the supply or composition of breastmilk, and/or affects infant growth.

Eligibility (Inclusion): 18 years and older, speak English or Spanish, had a vaginal or cesarean delivery of a singleton full-term (>37weeks) infant less than 168 hours prior.

Eligibility (Exclusion:) Patients who desire another pregnancy in less than 6 months, do not intend to exclusively breastfeed, do not have access to a smartphone, email or telephone, or have any medical contraindication to progestin-only pills (POPs) per the U.S. CDC MEC or any contraindication to breastfeeding. In addition, people with known current illegal maternal drug use, a history of breast reduction or augmentation, or an infant with a major congenital anomaly due to unique challenges with breastfeeding.

⚲

Description: Intrauterine devices (IUDs) are historically placed at the six-week postpartum (PP) visit for women who desire intrauterine contraception. Some women are already pregnant at that time. The early postpartum period (EPP), 2-4 weeks after delivery, could be a convenient time for women to receive contraception, including IUDs. Offering women EPP IUDs may decrease the risk of undesired pregnancy and rapid repeat pregnancy.

Eligibility (Inclusion): Patients who gave birth less than or equal to 10 days ago, desires an IUD for contraception (either copper or levonorgestrel contraining), willinf and able to sign an informed consent, willing to comply with the study protocol, age great than or equal to 18 years, English or Spanish speaking.

Eligibility (Exclusion): Uterine anomaly or leiomyomata which would not allow placement of an IUD, desire for repeat pregnancy in less than 6 months, evidence of intra-uterine infection (chorioamnionitis or postpartum endometritis) treated with antibiotics, ruptured uterus at the time of delivery, received a postpartum tubal ligation or immediate postpartum IUD or implant at delivery, incarcerated women or women with significant cognitive impairment, 4th degree perineal laceration sustained at delivery, any medical contraindication to IUD per the US CDC Medical Eligibility Criteria, any suspicion for new pregnancy  

⚲

Description: To assess baseline clinician knowledge regarding Rh testing in early pregnancy and understand barriers impeding practice changes regarding Rh testing in early pregnancy.

Eligibility (Inclusion): ObGyn Clinicians in academic medical settings

⚲

Description: To describe motivations, influences, barriers, impact of abortion restrictions, and technology use for nulliparous patients under the age of 30 seeking permanent femal contraception.

Eligibility (Inclusion): Clinicians who see patients seeking permanent female contraception.

⚲

Description: To better understand the abortion risk profile for women with high-risk pregnancies. A collaboration with other UC medical centers.

Eligibility (Inclusion): 18 years or older; Less than 23 weeks and 6 days; Having had one of the following ICD-10 procedures (59840, 59841, 59820, 59821)

Eligibility (Exclusion): If they underwent an induction termination or a medication abortion; If they underwent admission or procedure as a result of an outside facility transfer

⚲

Description: To assess the effect of the Dobbs decision on OBGYN residency abortion training
in the United States from the perspective of Ryan Residency directors and Residency Program Directors.

Eligibility (Inclusion): Directors of ob/gyn residency programs

⚲

Description: To assess the potential for a peer support doula (trained in pain management, self-compassion, and emotional support techniques) as a possible early pregnancy loss (EPL) intervention that could result in improved emotional wellbeing and ability to cope post-EPL

Eligibility (Inclusion): reproductive aged women 18-50 years old who experienced an EPL in the past two years and are able to consent in English

⚲

Description: To explore telemedicine for contraception care, focusing on the experience of patients who speak Spanish.

Eligibility: in development

⚲

Description: Exloration of barriers and facilitators of IUD extended use from patient and clinician perspectives.

Eligibility: 

⚲

Description: Phase 3 trial of a investigational gel to prevent transmission of gonhorrhea and chlamydia.

Eligibility:

⚲

Description: To understand barriers, facilitators, and experiences of clinicians, patients, and health systems to implement and utilize extended use of the contraceptive implant.

Eligibility (Inclusion): Over 18. Nexplanon user. Has appointment to replace nexplanon.

Eligibility (Exclusion): Has had nexplanon for less that 32 months or more than 40 months.

⚲

Description: This multi-site study linked Contraception method use with the national Cystic Fibrosis patient registry.

Eligibility: 

Description: In this study we had participants track their menstrual cycle & Cystic Fibrosis symptoms in the same App to see if there an association.

Eligibility:

Description: In this multi-site study we retrospectively looked pregnancy outcome & Cystic Fibrosis (CF) symptom severity among individuals with CF.

Eligibility:

Description: RCT study. We evaluated whether Buprenorphine added to paracervicel block made a difference in patients' perceptions of pain during dilator insertion.

Eligibility:

Description: We partnered with refugee women from East Africa and Middle East to learn what type of reproductive health care information would be most helpful to their communities.

Eligibility:

Description: We drew blood samples from our patients with epilepsy who are DMPA users to evaluate how their epilepsy medications interact with their levels of DMPA.

Eligibility (Inclusion): Diagnosis of epilepsy, current user of DMPA

Description: This study is examining the use of ACR-368 in patients with platinum resistant recurrent ovarian cancer. The trial is trying to also determine the potential utility of an OncoSignature on predicting response to treatment

⚲

Description: Preliminary evidence suggests that glucocorticoid receptor antagonists, when combined with chemotherapy can improve outcomes in patients with platinum resistant recurrent ovarian cancer. This trial is examining the potential benefit of combining Relacorilant with Nab-Paclitaxel in platinum resistant recurrent ovarian cancer.

⚲

Description: Clear cell and endometrioid ovarian cancers are difficulct to treat malignancies. This trial is examining a novel drug, NXP-800 in the treatment of ARID1a mutated clear cell and endometrioid ovarian cancer.

⚲

Description: In development

Eligbility: THIS TRIAL IS CLOSED TO ACCRUAL

Description: In development

Eligbility: THIS TRIAL IS CLOSED TO ACCRUAL

Description: TISSUE COLLECTION STUDY

Description: Immunotherpay remains an attractive treatment option for many cancer types. This trial is examining a novel, bi-specific immunotherapy drug, XmAb20717, in patients with gynecologic malignancies

⚲

Description: This clinical trial is looking to determine if the robotic laparoscopic platform is safe in the surgical management of appropriately selected cervical cancer patients.

⚲

Description: Wee-1 inhibitors have shown proise as treatment strategies in the management of platinum resistant, recurrent ovarian cancer.  This trial is looking to examine the efficacy of ZN‑c3, a wee-1 inhibitor, in platinum resistant recurrent ovarian cancer

Description: In development.

Elibility: THIS STUDY IS CLOSED

Description: Antibody drug conjugates have emerged as an appealing treatment strategy in the management of ovarian cancer. Mirvetuximab is already approved in FR-alpha high recurrent, platinum resistant ovarian cancer. This trial is examining the potential use of mirvetuximab in combination with carboplatin in patients with lower FR-alpha expression levels.

Description: Antibody drug conjugates have emerged as an appealing treatment strategy in the management of ovarian cancer. Mirvetuximab is already approved in FR-alpha high recurrent, platinum resistant ovarian cancer. This trial is examining the potential use of mirvetuximab in combination with bevacizumab as a maintenance treatment in patients with FR alpha high, recurrent platinum sensitive ovarian cancer

Description: In development

Eligibility: THIS STUDY IS CLOSED

Description: In development

Eligibility: THIS STUDY IS CLOSED

Description: In development

Eligibility: THIS STUDY IS CLOSED

Description: In development

Eligibility: THIS STUDY IS CLOSED

Description: In development

Eligibility: THIS STUDY IS CLOSED

Description: In development

Eligibility: THIS STUDY IS CLOSED

Description: This is a retrospective study looking to examine the potential benefit of Heated Intraperitoneal Chemotherapy (HIPEC) based on their Tumor-Intrinsic Chemosensitivity (KELIM)

Description: In development

Description: In development

Eligibility: THIS STUDY IS CLOSED

Description: This is a retrospective study exploring the clinical outcomes for in patient vs out patient LEEP

Eligibility: THIS STUDY IS CLOSED

Description: In development

Eligibility: THIS STUDY IS CLOSED

Description: In development

Eligibility: THIS STUDY IS CLOSED

Description: In development

Eligibility: THIS STUDY IS CLOSED

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

⚲

Description: in development

Eligibility: in development

⚲

Description: This study seeks to identify maternal and intrapartum factors associated with successful versus failed induction TOALC, and with induction TOLAC compilations, among women undergoing induction TOLAC. An examination of the maternal and obstetrical factors among women undergoing induced TOLAC which are associated with successful outcomes will allow clinicians to stratify which patients are good candidates for induction TOLAC, providing them with the benefits of TOLAC, while sparing other women from the risks of failed or complicated TOLAC.

Eligibility (Inclusion): persons with a prior cesarean section undergoing an induction of labor either electively or for medical indication after 34 weeks with a live, singleton gestation in cephalic presentation.

Eligibility (Exclusion): persons with multiple gestation, fetal demise, malpresentation, contraindication to vaginal delivery, those who present with spontaneous labor, cases of labor augmentation, those who undergo planned elective repeat cesarean section, or for whom available data is insufficient.

⚲

Description: This study aims to evaluate the relationship between postpartum mental health and wellbeing and perceived control over delivery (labor agentry). Subjects will be enrolled early in the third trimester and given surveys to complete at on enrollment, immediately after delivery, and at 6 weeks postpartum.

Eligibility (Inclusion): Patients must be 28-32 weeks gestational age, English or Spanish speaking, over 18 years old, not planning on a cesarean delivery, and see high risk OB (MFM) for prenatal care.

Eligibility (Exclusion): Planning a cesarean section, under 18, primary language other than English or Spanish, see a prenatal provider who is not a high risk OB

⚲

Description: To test the Periviable GOALS (Getting Optimal Alignment around Life Support) decision support tool versus usual care among pregnant women who are hospitalized for potential periviable delivery.

Eligibility (Inclusion):

• 18 years of age or older
• At risk for delivery between GA 22.0-23.6
• Counseled by NICU and MFM regarding resuscitation options

⚲

Description: There is little information on long-term pulmonary outcomes of children born in the late preterm period, and no data on the effects of antenatal betamethasone exposure when administered in the late preterm period. Therefore, this study is designed to conduct an assessment of pulmonary outcomes on children whose mothers participated in the MFMU Network ALPS trial to determine whether the neonatal benefit of antenatal corticosteroids is sustained into childhood.

Eligibility: in development

⚲

Description: Observational study regarding the use of Extracorporeal Membrane Oxygenation system for COVID-19 infection in pregnancy

Eligibility: in development

⚲

Description: Development of a blood test to identify maternal plasma markers that are predictive of fetal age and pregnancy complications like preterm birth and preeclampsia.

Eligibility: in development

Description: The PreTRM test is a blood test that lookds at certain proteins in the blood and predicts the risk of giving birth preterm (<37wk GA). All women will have blood collected but only half will receive the test result. Those who get a Higher risk result will be offered the intervention.

Eligibility (Inclusion):

• 18 years of age or older
• Gestational age18 0/7 to 20 6/7 weeks
• Singleton intrauterine pregnancy
• No signs and/or symptoms of preterm labor and has intact membranes

Description: This study aims to evaluate the feasibility and utility of an oral lipid challenge test between 16-24 weeks gestation to predict development of preclampsia in high risk patients. The study involves ingestion of an oral lipid challenge drink with 3 timed blood draws (BL, 1hr, 4hr) and brief diet and exercise surveys.

Eligibility: in development

Description: The aim of this study is to examine characteristics of pre and post-natal imaging that may be used to predict adverse outcomes and to compare the performance and pre and post natal imaging for diagnosis and prognostication of these conditions.

Eligibility: in development

Description: This study will allow research to be done using data from imaging examinations that have been or will be performed for clinical care and compare to outcomes identified from medical records.

Eligibility: in development

Description: Obstetric laceration identification and categorization: in this study, we examine whether we can improve obstetric laceration identification and diagnosis with a brief instructional video.

Eligibility: in development

Description: To develop strategies to identify postpartum women at risk for adverse cardiovascular outcomes and provide them with preventative therapies. Participation in the study will begin no later than the second trimester of pregnancy (enrollment by 24 weeks of gestation) and continue through the first year postpartum. Over the course of the study, biospecimens and relevant surveys and cardiovascular assessments will be collected at specified intervals/time-points.

Eligibility (Inclusion):

• Pregnant women 18 years of age to 50 years of age
• 10-24 weeks gestation at time of enrollment
• Singleton pregnancy
• Planning to deliver at a study site

Eligibility (Exclusion):

• Inability to give informed consent
• Intrauterine fetal demise
• Fetal genetic or structural anomaly
• Institutionalization for psychiatric disorder, mental deficiency or incarcerated
• Active or history of malignancy requiring major surgery or systemic chemotherapy
• Multi-fetal gestation or a twin demise at any gestational age
• Known maternal or fetal chromosomal anomalies
• Patients who plan to keep their placenta after delivery

Description: The purpose of this study is to offer sustainable COVID-19 testing convenience in the greater San Diego community. This will be a flexible and sustainable approach that promotes responsiveness to both the needs of the community and the changing pandemic context while reducing COVID-19 disparities.

Eligibility (Inclusion):

• Age 18 years or older
• Speak Spanish or English
• Cohort 2 Testing Group:
• Speak Spanish and/or English.
• Affiliated with San Ysidro Health as a patient at select clinics (San Ysidro, Chula Vista, Lincoln Park, and Logan Heights) OR
• A member of a community near a SYH clinic (San Ysidro, Chula Vista, Lincoln Park, and Logan Heights).
• Ages 2 and older (for use of FDA-authorized antigen test kits)
• Cohort 3 Healthcare Providers/Staff/Administrators:
• Speaks Spanish and/or English.
• Employed as a SYH clinical provider, administrator, or clinical staff member at a participating clinic

Description: This is a multicenter collaboration designed to discover genetic diseases and novel variants underlying non-immune hydrops fetalis (NIHF) and other fetal effusions in a prospectively cohort utilizing genomic sequencing and RNA sequencing.

Eligibility (Inclusion): Non-diagnostic results of chromosomal microarray and/or karyotype and No evidence of:

• Clinically significant abruption that is suspected to underlie NIHF
• Twin-twin transfusion syndrome in monochorionic twins;
• Clear fetal viral infection;
• Alloimmunization.

AND ONE OF THE FOLLOWING

• i) Increased nuchal translucency or cystic hygroma ≥5 mm WITHOUT any additional fetal effusions or anomalies;

AND/OR

• ii) Increased nuchal translucency or cystic hygroma ≥3.5 mm AS WELL AS either any additional fetal effusions or congenital anomalies;

AND/OR

• iii) Fetal ascites, pleural effusion, pericardial effusion, AND/OR skin edema identified at any point during gestation, prior to the conclusion of the pregnancy.

Description: The purpose of this study is to collect blood samples from volunteers to develop a new noninvasive prenatal test that can detect these genetic abnormalities in blood samples..

Eligibility (Inclusion):GA≥10Wks, available results form NIPT standard

Eligibility (Exclusion):Failure to meet inclusion criteria

Description: To demonstrate the use of a non-invasive, wearable continuous fetal hemodynamics monitor. The long-term goal is to apply this system for at-home monitoring, which will allow clinicians to properly assess and manage response to treatment in fetal complications such as hypoxia, growth restrictions, or pre-eclampsia.

Eligibility (Inclusion):

• Female age ≥18 years of age
• Able to provide informed consent
• Fetal gestational age 24-42 weeks at time of consent
• Surrogates and/or use of donor eggs/donor sperm for conception is allowed

Description: The purpose of this study is to collect tissue samples for Angiocrine Bioscience, who will then perform research to determine the potential for cells isolated from the umbilical cord tissue to regenerate cells within the hematologic (blood) system and to repair various tissues and organs in the body that are damaged by disease.

Eligibility (Inclusion):

• Female age >18 years of age
• Able to provide informed consent
• Able to provide acceptable answers to Donor/Subject Questionnaire
• Giving birth at a licensed hospital-based Labor and Delivery (L&D) Unit
• Neonatal gestational age 24-42 weeks at time of consent
• History of prolonged rupture of membranes with no maternal fever before birth is allowed
• History of maternal diabetes or hypertension is allowed
• Surrogates and/or use of donor eggs/donor sperm for conception is allowed
• Multiple gestation pregnancy is allowed

Description: The purpose of this study is to determine if certain ultrasound findings, clinical data and biomarkers present in biospecimens such as urine, blood and placenta can help predict the outcome of pregnancy. A biospecimen bank and associated database have been created under this protocol and will be used for biomarker discovery and/or validation. Placental stem cells will be used for investigation of the different cell types that are made during embryo and placental development and will be used to study placental dysfunction.

Eligibility (Inclusion):

• Pregnant patients ≥ 18 years of age.
• Agrees to allow for the placenta to be sent to Pathology for evaluation.

Inclusion criteria for the Non-pregnant group:

• Non-pregnant women ≥ 18 years of age.
• Healthy women with no previous history of chronic hypertension or renal disease.

Description: This project will look at changes in levels of biomarkers (e.g. exRNAs and proteins) in biofluid samples collected from pregnant women from 38 to 42 weeks gestation. We will analyze these data to identify biomarkers to predict when a woman will go into labor.

Eligibility: GA 38.0 to 38.3; singleton pregnancy; healthy women with no previous poor pregnancy outcome

Description: The purpose of this study is to determine whether circulating biomarkers in the maternal blood, with or without specific ultrasound findings and clinical data, can accurately distinguish pregnancies affected by placenta accreta from pregnancies affected by placenta previa (placenta covering the cervix) without accreta and from pregnancies with normally located placentas. A biospecimen bank and associated database will be created under this protocol and will be used for biomarker discovery and/or validation.

Eligibility: Inclusion criteria for cases:

• Pregnant women ≥18 years of age
• Presenting for care in one of the listed health care systems
• Diagnosis of suspected placenta accreta, diagnosed by ultrasound or magnetic resonance imaging
• Planning to deliver within the listed health care system
• Agrees to allow for the placenta to be sent to Pathology for evaluation

Description: in development

Eligibility: in development

⚲

Description: in development

Eligibility: in development

⚲

Description: Evaluations of reproductive hormones and ovulation in transgender men before and during testosterone treatment; comparison with cisgender women

Eligibility: Transgender men initiating therapy or cisgender women, age 18-35, BMI 18-29, no endocrinopathy

⚲

Description: Evaluations of reproductive hormones and ovulation in transgender men before and during testosterone treatment; comparison with cisgender women

Eligibility: in development

⚲

Description: Via linking the national IVF dataset (SART) with data from the Walgreens Heart Beat Program, we aim to compare utilization of ART oocyte and embryo banking prior to gonadotoxic treatment cycles and Heart Beat Program before and after the effective date of state fertility preservation mandates

Eligibility (Inclusion): N/A

⚲

Description: The objectives are: 1) Test the feasibility of ecological momentary assessment (EMA) to measure psychosocial stress in females with infertility, and 2) Estimate the association between psychosocial stress and follicular phase length and ovulation.

Eligibility (Inclusion): Ages 18-42, regular menstrual cycles, undergoing in vitro fertilization

⚲

Description: The objectives are: 1) Assess the feasibility, acceptability, appropriateness of and satisfaction with a health insurance education intervention on in vitro fertilization (IVF) insurance benefits; 2) Explore the effectiveness of a health insurance education intervention on health insurance literacy and IVF utilization.

Eligibility (Inclusion): University of California, San Diego staff or faculty, ages 18-50, intention to attempt pregnancy over the next year

⚲

Description: Conduct a hybrid type 1 effectiveness-implementation trial of a telehealth intervention for oncofertility care in three hospital systems

Eligibility (Inclusion): Ages 0-50, newly diagnosed cancer patient, oncology care at UC San Diego, Rady Children's or City of Hope

⚲

Description: Conduct an interrupted time series trial of a multi-component intervention to deliver women’s health care to rural breast cancer survivors

Eligibility (Inclusion): Ages 0-50, breast cancer survivor, female

Description: This is a multi-center prospective cohort study following psychosocial and reproductive otucomes in individuals who undergo ovarian tissue cryopreservation for fertility preservation

Eligibility (Inclusion): Ages 0-42, undergoing ovarian tissue cryopreservation

Description: Conduct an interrupted time series trial of a reproductive health survivorship care plan for Hispanic, rural female survivors of adolescent and young adult cancer

Eligibility: Ages 0-39, AYA cancer survivor, undergoing care at El Centro Regional Medical Center

Description: A prospective cohort study using biomarkers to predict ovarian function outcomes in young breast cancer survivors

Eligibility: Ages 0-45, breast cancer, has uterus and at least one ovary

Description: Using spent media in IVF culture, this study sought to measure cell free RNA and relate biomarkers to IVF outcomes.

Eligibility (Inclusion): IVF with embryo culture

Description: This clinical trial tested if a remotely-delivered survivorship care plan on estrogen deprivation symptoms, fertility concerns, contraception and sexual health improved reproductive outcomes in breast cancer survivors

Eligibility: Ages 0-45, breast cancer

Description: This prospective cohort study aimed to characterize the pattern of ovarian function post-treatment in adolescent and young adult cancer survivors.

Eligibility: Ages 15-40, AYA cancer, female, has uterus and at least one ovary

Description: This prospective cohort study aimed to test ovarian reserve in the pill-free week in AYA cancer survivors to see if we can measure ovarian reserve accurately without stopping combined hormonal contraception

Eligibility: Ages 15-40, AYA cancer, female, has uterus and at least one ovary

Description: This prospective cohort study measured patient reported reproductive outcomes in a national cohort of female AYA cancer survivors

Eligibility: Ages 15-40, AYA cancer, female

Description: Assess the association between social determinants of health and fertility preservation health insurance benefit designs and access.

Eligibility: Ages 0-50, newly diagnosed cancer patient, oncology care at UC San Diego, Rady Children's or City of Hope

Description: To characterize multi-level implementation of state-level health insurance benefit mandates for fertility preservation

Eligibility (Inclusion): Newly diagnosed cancer patients, parents/guardians, oncology and fertility clinic members

Description: EDeveloping a stem cell approach to confer fertility to infertile male patients. Spermatogonial stem cells (SSCs) are essential for the continuous generation of sperm. Thus, there is tremendous interest in generating a SSC-based therapy to treat male infertility. Two key challenges in developing SSC therapy are (i) the identification of specific markers that label human SSCs (so they can be identified and purified), and (ii) development of methods to culture human SSCs. We are actively working on both these challenges. In order to do so, it is essential we have testicular biopsies as a source of SSCs.

Eligibility: in development

Description: Optimizing a rapid diagnostic test—only requiring semen, not a testes biopsy—that will tell your doctor whether you have a spermatogenic defect and, if so, whether it is treatable. For example, if your semen has no sperm and our molecular diagnostic test indicates that you have “testicular sperm” (technically, called “elongated spermatids”), you will be a strong candidate for the microdissection testicular sperm extraction (mTESE) procedure. This mTESE procedure, coupled with intracytoplasmic sperm injection (ICSI), has the potential to allow you to father children. An added feature of the diagnostic test we are developing is that it will determine how “mature” your testicular sperm are. Mature testicular sperm are probably more likely than immature testicular sperm to fertilize an egg. Thus, our diagnostic test has the potential to predict the likelihood that you will father children through the mTESE + ICSI procedure.

Eligibility: in development

Description: In development

Eligibility:In development

⚲

Description: In development

Eligibility:In development

⚲

Description: In development

Eligibility:In development

Description: In development

Eligibility:In development

Description: In development

Eligibility:In development

Description: In development

Eligibility:In development

Description: In development

Eligibility:In development

Description: In development

Eligibility:In development

Description: The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months.

Eligibility:

1. 18 years or older
2. report at least "quite a bit bothered" or worse by their UUI defined by response to OAB-q-SS item #8 "How bothered are you by urine loss associated with a strong desire to urinate?"
3. are not and do not plan to become pregnant
4. have persistent UUI defined as previous unsuccessful results after conservative and anticholinergic treatment, or are unable to tolerate or have contraindications to anticholinergics
5. are currently not taking anticholinergics or are willing to stop medication for 3 weeks prior to enrollment.

Discover "BEST" RESEARCH STUDY

Description: The RISE FOR HEALTH study (RISE) is an initiative of the Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium, which was formed by the NIDDK in 2015 to develop the science to improve bladder health in women and girls. RISE is designed to identify risk and protective factors for bladder health and lower urinary tract symptoms (LUTS) and to estimate the distributions of bladder health and bladder health knowledge, attitudes, and beliefs in women of all ages across the life course.
This will be accomplished by conducting a population-based prospective cohort study. A sample of individuals who live within the study base, i.e., the county containing each PLUS clinical research center and each adjacent county, will be invited to complete two baseline surveys and then two follow-up surveys one year later. A subset of participants will be invited to attend an in-person evaluation to collect additional clinical information and biologic specimens.

Eligibility (Inclusion): 

1. Community dwelling
2. Age ≥18 years
3. Identify or born as female (includes cis- and trans-women, and trans-men)
4. Able to read and understand English or Spanish
5. Able to read and provide informed consent

Description: The primary aim is to compare the effectiveness of intradetrusor injection of 100 unit injection of Botulinum toxin A to mid-urethral sling for change in MUI symptoms 6 months following treatment.

Eligibility (Inclusion):

1. Reporting at least "moderate bother" from UUI item on UDI "Do you experience urine leakage associated with a feeling of urgency?"
2. Reporting at least "moderate bother" from SUI item on UDI "Do you experience urine leakage related to physical activity, coughing, or sneezing?"
3. Diagnosis of SUI defined by a positive cough stress test (CST) or UDE within the past 18 months
4. Presence of UUI on bladder diary with > 4 Urgency IE/3-day diary
5. Urinary symptoms >3 months
6. Persistent symptoms despite at least one or more conservative treatments (e.g. supervised behavioral therapy, physical therapy) as determined adequate by the physician.
7. Inadequate response to oral overactive bladder medications (including anti-cholinergic and/or beta-mimetic medication) unless patient is intolerant of oral overactive bladder medications, or oral overactive bladder medications are contraindicated as determined by the treating provider.
8. Urodynamics within past 18 months
9. Demonstrates ability (or have caregiver demonstrate ability) to perform clean intermittent self-catheterization.

Description: The study is a multi-center, randomized, surgical trial of women with symptomatic post-hysterectomy apical (cuff) prolapse desiring surgical treatment. This study will compare the three available surgical treatments performed in usual practice. The purpose of this study is to compare two commonly performed mesh apical repair (sacral colpopexy vs. Apical Transvaginal Mesh) and vaginal native tissue apical repairs with mesh reinforced repairs. The primary outcome is measured over time (up to 60 months) using a survival analysis approach.

Eligibility (Inclusion):

1. Women age 21 or older
2. Prior total hysterectomy (no cervix present)
3. Prolapse beyond the hymen (defined as Ba, C, or Bp > 0 cm)
4. Vaginal cuff descent into at least the lower two thirds of the vagina (defined as point C> -2/3 TVL)
5. Bothersome bulge symptoms as indicated on question 3 of the PFDI-20 form relating to 'sensation of bulging' or 'something falling out'
6. Desires surgical treatment for post-hysterectomy vaginal prolapse
7. Available for up to 60 month follow-up

Description: The primary purpose of this randomized clinical trial is to compare the effectiveness and safety of two transvaginal apical suspension strategies for uterovaginal prolapse: a mesh augmented hysteropexy versus vaginal hysterectomy and uterosacral ligament suspension (USLS). The primary aim is to determine whether treatment success in women who undergo the above strategies differ at time points through 3 years.

Eligibility (Inclusion):

1. Women aged 21 or older who have completed child -bearing
2. Prolapse beyond the hymen (defined as Ba, Bp, or C > 0 cm)
3. Uterine descent into at least the lower half of the vagina (defined as point C> -TVL/2) )
4. Bothersome bulge symptoms as indicated on question 3 of the PFDI-20 form relating to 'sensation of bulging' or 'something falling out'
5. Desires vaginal surgical treatment for uterovaginal prolapse
6. Available for up to 60 month follow-up
7. Amenorrhea for the past 12 months from either menopause or endometrial ablation
8. Not pregnant, not at risk for pregnancy or agree to contraception if at risk for pregnancy (only applicable to the rare endometrial ablation patient)
9. Eligible for no cervical cancer screening for at least 3 years

Description: The primary objective of this study is to perform cognitive interviews in conjunction with an electronic survey to test candidate survey items for inclusion in a bladder health measure that can assess the full range of bladder health and be considered for further reliability and validity testing. The secondary objective is to carry out cognitive interviews/surveys to test key risk and protective factor candidate survey items capable of assessing risk and protective factors for bladder health.

Eligibility (Inclusion):

1. Female sex assigned at birth
2. Fluent in written and spoken English (may be bilingual)
3. Age ≥18 years old
4. Available for a virtual 2 hours interview and questionnaire completion
5. Able to read and provide either verbal or written informed consent
6. Virtual interviews: Access to the computer with Internet, audio and video capabilities for participants who will be completing their Cis virtually

Description: In development

Eligibility (Inclusion):In development

Eligibility (Inclusion):

1. Age ≥18 years
2. Identify or born as female
3. Age ≥18 years old

Eligibility (Exclusion):

• Physical or mental condition that would impede participant to provide urine sample

Description: in development

Eligibility: in development

Description: We aim to assess the association of third-year medical student clerkship grades, standardized test scores, and evaluations with personality assessments of introversion and communication apprehension.

Eligibility: Current medical students at UCSD

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in development

Eligibility: in development

Description: in abdominal myomectomies in which a tourniquet is used, is there any effect on ovarian reserve measured by AMH levels. An AMH is checked preop and 3 months postop

Eligibility: in development

Description: in development

Eligibility: in development

Description: Recruitment for OB providers and nursing to participate in virtual reality based OB hemorrhage simulation.

Eligibility: in development

Description: Our hypothesis is that a supracervical approach will be associated with less morbidity including urologic and gastrointestinal injury, overall operative time, and blood transfusion. We will also explore other predictors for morbidity at the time of cesarean hysterectomy including maternal characteristics, timing and indication for delivery, indication for hysterectomy, location of hysterectomy, and primary surgical team

Eligibility: cesarean hysterectomy